{"id":33190,"date":"2026-03-16T17:09:27","date_gmt":"2026-03-16T17:09:27","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/33190\/"},"modified":"2026-03-16T17:09:27","modified_gmt":"2026-03-16T17:09:27","slug":"novartis-nvs-enters-1-7-billion-development-deal-says-report","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/33190\/","title":{"rendered":"Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report"},"content":{"rendered":"\n

We recently published 13 Best ADR Stocks to Invest In<\/a>.\u00a0 Novartis AG (NYSE:NVS) is one of the best ADR stocks.<\/p>\n

Swiss pharmaceutical giant Novartis AG (NYSE:NVS) has entered into a massive $1.7 billion partnership with British pharmaceutical firm Relation Therapeutics to develop treatments for allergic diseases, according to a report from Bloomberg which surfaced on December 9th. Through this deal, the firm will use Relation\u2019s AI platform to develop new drugs by studying the genetics involved in diseases.<\/p>\n

\"Novartis Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report <\/p>\n

A day earlier, Novartis AG (NYSE:NVS)\u2019s shares were upgraded to Overweight from Neutral by investment bank JPMorgan. As part of its coverage, the bank also raised the firm\u2019s share price target to CHF125 from an earlier CHF95 as it based its optimism on the back of positive sentiment regarding the firm\u2019s outlook for 2026.nNovartis AG (NYSE:NVS) has been busy with partnerships in 2025 as its deal with Relation isn\u2019t the only one that it has inked. For instance, the firm bought Avidity Biosciences for a whopping $12 billion price tag in October. Through the deal, Novartis AG (NYSE:NVS) aims to boost its RNA drug development portfolio to cover rare ailments such as the Duchenne Muscular Atrophy. Apart from the Avidity deal, the Swiss pharma firm has also entered into agreements to buy Tourmaline Bio for $1.4 billion for its cardiovascular portfolio and Regulus Therapeutics for a $1.7 billion price tag to boost its renal portfolio.<\/p>\n

While we acknowledge the potential of NVS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock<\/a>.<\/p>\n

READ NEXT: 30 Stocks That Should Double in 3 Years<\/a> and

Insider Monkey<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"We recently published 13 Best ADR Stocks to Invest In.\u00a0 Novartis AG (NYSE:NVS) is one of the best…\n","protected":false},"author":2,"featured_media":33191,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[19689,206,1078,7846,19690],"class_list":{"0":"post-33190","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-allergic-diseases","9":"tag-novartis","10":"tag-novartis-ag","11":"tag-regulus-therapeutics","12":"tag-relation-therapeutics"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116239962113734525","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/33190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=33190"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/33190\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/33191"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=33190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=33190"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=33190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}